Mitral Valve Diseases

Global Mitral Valve Diseases Market to Reach US$4.7 Billion by 2030

The global market for Mitral Valve Diseases estimated at US$3.1 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Mitral Valve Repair, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Mitral Valve Replacement segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$834.8 Million While China is Forecast to Grow at 11.7% CAGR

The Mitral Valve Diseases market in the U.S. is estimated at US$834.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Mitral Valve Diseases Market – Key Trends & Drivers Summarized

Why Are Mitral Valve Diseases Emerging as a Critical Focus in Global Cardiovascular Care?

Mitral valve diseases, encompassing both mitral regurgitation (MR) and mitral stenosis (MS), represent a significant burden in the global spectrum of cardiovascular disorders. The mitral valve—situated between the left atrium and left ventricle—regulates unidirectional blood flow through the heart. Any structural or functional abnormalities in this valve can result in regurgitation (leakage) or stenosis (narrowing), ultimately impairing cardiac output and contributing to symptoms such as fatigue, dyspnea, palpitations, and pulmonary hypertension. Left untreated, these disorders progress to congestive heart failure and increased mortality risk.

Aging populations, rising rates of hypertension and atrial fibrillation, and improved imaging diagnostics are contributing to the increased detection and prevalence of mitral valve diseases. In developed countries, degenerative MR associated with mitral valve prolapse is more common, whereas in lower-income settings, rheumatic mitral stenosis remains a persistent issue due to limited access to early treatment and preventive care. The clinical importance of timely identification and management is growing, particularly with expanding therapeutic options that now include minimally invasive surgical and transcatheter procedures.

How Are Diagnostic and Therapeutic Advancements Reshaping the Treatment Pathway for Mitral Valve Disorders?

The diagnostic landscape for mitral valve diseases has significantly improved with the widespread availability of transthoracic and transesophageal echocardiography, 3D imaging, and cardiac MRI. These tools allow accurate assessment of valvular anatomy, leaflet motion, chamber dimensions, and regurgitant volume, enabling earlier detection and classification of disease severity. Risk scoring systems and multi-parametric evaluations are now central to treatment planning, guiding decisions between watchful waiting, pharmacologic management, and interventional therapy.

Surgical repair or replacement has long been the standard of care for severe mitral valve disease, particularly for patients with preserved ventricular function. However, innovations in transcatheter mitral valve interventions (TMVI), such as MitraClip, PASCAL, and valve-in-ring/valve-in-mitral annular calcification (ViR/ViMAC) procedures, are transforming treatment for high-risk patients who are not candidates for open surgery. Advances in robotic-assisted repair, chordal replacement systems, and annuloplasty rings are improving procedural safety and outcomes. Pharmacological management remains important in earlier stages or for symptomatic relief in non-operable patients, with beta-blockers, diuretics, and anticoagulants being frequently employed.

Which Patient Segments and Geographic Markets Are Most Affected and Driving Care Demand?

Mitral valve diseases disproportionately affect the elderly, particularly individuals above 65 years of age, many of whom present with multiple comorbidities such as diabetes, hypertension, or ischemic heart disease. MR is more prevalent in developed economies where life expectancy and degenerative diseases dominate, while rheumatic MS continues to impact younger populations in parts of Africa, South Asia, and Latin America. Additionally, women are more frequently diagnosed with mitral valve prolapse, which may progress to regurgitation in older age.

North America and Western Europe dominate the market due to well-established cardiovascular infrastructure, reimbursement mechanisms, and high diagnostic penetration. These regions are also leading in TMVI adoption. Asia-Pacific is witnessing growing demand due to aging demographics, increasing procedural capacity, and rising awareness of structural heart disease. In emerging markets, public health campaigns, mobile diagnostic units, and rheumatic heart disease screening initiatives are helping expand access to care. These efforts are especially important in rural and underserved regions, where mitral diseases often go undiagnosed until advanced stages.

What Is Driving Long-Term Growth in the Global Mitral Valve Diseases Market?

The growth in the mitral valve diseases market is driven by rising disease incidence, technological progress in imaging and intervention, and the convergence of clinical innovation with demographic aging. Expansion of heart failure programs, structural heart clinics, and multidisciplinary heart teams is allowing earlier and more personalized treatment interventions. Increasing regulatory approvals and reimbursement coverage for TMVI devices are accelerating their use in both primary and secondary MR cases.

Global clinical trials are expanding the evidence base for early intervention, particularly for functional MR associated with heart failure. Additionally, the development of transcatheter mitral valve replacement (TMVR) devices is unlocking new frontiers in treating anatomically complex or previously inoperable patients. Patient-centric innovations—including same-day discharge protocols, real-time monitoring, and telecardiology follow-ups—are improving long-term care delivery and reducing hospitalization costs.

As cardiology shifts toward preventative, less invasive, and outcomes-focused models, mitral valve disease management is set to remain a cornerstone of cardiovascular innovation and clinical investment—balancing quality of life, procedural safety, and healthcare economics.

SCOPE OF STUDY:

The report analyzes the Mitral Valve Diseases market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics); Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation); End-User (Hospitals, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• 4C Medical Technologies
• Abbott Laboratories
• Affluent Medical
• Anteris Technologies
• Artivion, Inc.
• Bayer AG
• Boston Scientific Corporation
• Braile Biomedica
• Cadrenal Therapeutics, Inc.
• Colibri Heart Valve LLC
• Corcym UK Limited
• Edwards Lifesciences Corporation
• HighLife Medical
• Labcor Laboratórios Ltda
• Lepu Medical Technology Co., Ltd.
• LivaNova PLC
• Medtronic plc
• Micro Interventional Devices, Inc.
• Novartis AG
• Zydus Lifesciences Limited

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.